Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Chinese R/R B‑cell Malignancies (Phase I/II)
CTR20181987Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), B-cell lymphoma (BCL), sponsored by AstraZeneca. Started Jun 2019; status: completed.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)B-cell lymphoma (BCL)
Beyond the preview
Go deeper on CTR20181987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181987.